Marjaana S.
- Country
- Finland
- Department
- Olulu University Hospital,Cancer center Department of Haematology
Research Overview
- Evaluation of Minimal Residual Disease in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients Treated with Ixazomib, Lenalidomide, and Dexamethasone
- Phase 3 Open-Label Study of Elranatamab vs. Elotuzumab, Pomalidomide, Dexamethasone, or Carfilzomib in Relapsed/Refractory Multiple Myeloma Post Anti-CD38 Therapy
- Phase 3 Randomized Trial of Bortezomib, Lenalidomide, Dexamethasone, and Ciltacabtagene Autoleucel in Newly Diagnosed Multiple Myeloma Without Planned Stem Cell Transplant
Data & Insights
Has run more than one trial at 151 of 293 partner sites.
Specializations
Multiple Myeloma Treatment Development
This investigator specializes in evaluating novel therapeutic approaches for multiple myeloma, with particular focus on emerging treatments for both newly diagnosed and relapsed/refractory cases.
- Novel Therapeutic Combinations
- Post-Transplant Treatment Strategies
- Immunotherapy Applications
Primary interest lies in assessing innovative treatment combinations including elranatamab and daratumumab based regimens.
Blood Cancer Therapeutics
The investigator focuses on developing treatment protocols for relapsed/refractory multiple myeloma, exploring various therapeutic combinations to improve patient outcomes.
- Targeted Therapy Development
- Maintenance Treatment Strategies
- Disease Response Assessment
Expertise includes evaluation of minimal residual disease and progression-free survival outcomes.
Advanced Treatment Modalities
Research encompasses innovative approaches in hematologic oncology, particularly focusing on combination therapies and treatment sequencing.
- Treatment Optimization
- Clinical Response Evaluation
- Novel Drug Combinations
Special attention to autologous stem cell transplantation and its integration with modern therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.